The pharmaceutical company officially disclosed its annual report!

On the evening of January 20, the pharmaceutical and biological industry ushered in the first pharmaceutical company to officially disclose the 2021 annual report - Wohua Pharmaceutical.
The company's performance in 2021 was stable and slightly decreased, but at the same time as the annual report was released, Wohua Pharmaceutical also announced to the company.
The distribution plan for all shareholders to "distribute a cash dividend of 2.
60 yuan (tax included) for every 10 shares"
.
According to the annual report, in 2021, Wohua Pharmaceutical achieved operating income of 943 million yuan, a year-on-year decrease of 6.
3%; net profit of 163 million yuan, a year-on-year decrease of 8.
6%
.
The sales revenue of the main core products remained basically stable.
The sales revenue of Wohua® Xinkeshu tablets decreased by 7.
23% compared with the same period of last year, the sales revenue of Gushukang capsules/granules decreased by 22.
39% compared with the same period of last year, and the sales revenue of Hedan tablets/capsules decreased by 22.
39% compared with the same period last year.
In the same period, the sales revenue increased by 5.
82%, and the sales revenue of Naoxueshu oral liquid increased by 14.
53% compared with the same period of last year
.
Wohua Pharmaceutical is a Chinese patent medicine enterprise with a history of more than 200 years, integrating R&D, production and sales
.
The decline in performance was mainly due to the sharp rise in the prices of raw materials for Chinese herbal medicines, packaging materials, energy, etc.
, as well as unfavorable factors such as the interruption of the company's marketing due to the occasional regional epidemic
.
The report shows that since 2020, the prices of raw materials, packaging materials, and energy of traditional Chinese medicinal materials have continued to rise.
Some varieties have experienced a large price increase during the reporting period, and production costs have continued to rise
.
At the same time, driven by factors such as climate, rising commodity prices, and the suspension of imports due to the epidemic, the company's large-scale Chinese medicinal materials, especially wild Chinese medicinal materials, have risen significantly in price.
In addition, the current prices of crude oil, coal, and natural gas have risen by 46.
37% compared with the beginning of the year.
9.
52% and 49.
61%
.
These have greatly increased the procurement cost and management difficulty
.
However, Wohua Pharmaceutical also mentioned that during the reporting period, the company adhered to the "front-end-middle-stage-back-office" collaboration model based on changes in market prices, and continuously enriched and refined the tool library centered on "centralized procurement".
Purchasing and establishing reserve inventory, small and multiple dynamic procurement, annual consumption bidding, and expansion of direct procurement at the origin are all taken simultaneously, striving to reduce procurement costs and alleviate the impact of high manufacturing costs on operations
.
At the same time, arrange production more rationally, take energy-saving measures, improve energy efficiency and reduce energy use costs
.
It is worth mentioning that Wohua Medicine is continuing to increase investment in research and development, and continuously widen and deepen the "moat".
In 2021, the company's investment in research and development expenses will be 47.
4781 million yuan, an increase of 1.
67% over the same period of the previous year
.
At present, the company's research and development mode mainly includes independent research and development and joint research and development
.
Among them, in terms of independent research and development, the company has established the Wohua Pharmaceutical Research Institute of Traditional Chinese Medicine to attract outstanding scientific research talents, and has made achievements in the research and development of new varieties, in-depth development of old varieties, process optimization, patent application and registration, etc.
In terms of joint research and development, the company is committed to traditional Chinese medicine.
Innovation.
In recent years, it has successively cooperated with China Academy of Chinese Medical Sciences, Shandong Academy of Traditional Chinese Medicine, Shandong University, Tianjin University of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan University and other domestic scientific research institutions in talent training, laboratory co-construction, and new drug cooperation.
Industry-university-research cooperation in development, projects at all levels and scientific and technological plan project declaration, project research, and achievement transformation
.
In addition, the report also announced the company's profit distribution and capital reserve conversion to share capital.
The company's 2021 profit distribution plan is: Based on 577 million shares, a cash dividend of 2.
60 yuan (tax included) will be distributed to all shareholders for every 10 shares, and bonus shares will be distributed.
0 shares (tax included), and the capital reserve will not be converted into share capital
.